Novo Nordisk A/S : FDA posts briefing materials prior to Advisory Committee meeting for insulin degludec and insulin degludec/insulin aspart BAGSVAERD, DENMARK -- (Marketwire) -- 11/06/12 -- Novo Nordisk announced today that the US Food and Drug Administration (FDA) has published the briefing documents ahead of the Advisory Committee meeting to discuss the New Drug Applications (NDA) for insulin degludec and insulin degludec/insulin aspart, which will take place on 8 November 2012. The briefing documents from Novo Nordisk and the FDA, which will form the basis for the Advisory Committee's discussion, provide an overview of the non-clinical and clinical data for insulin degludec and insulin degludec/insulin aspart for the treatment of diabetes. Company Announcement No 71 2012: http://hugin.info/2013/R/1655401/534899.pdf This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Novo Nordisk A/S via Thomson Reuters ONE [HUG#1655401] Further information Media: Mike Rulis +45 3079 3573 email@example.com Ambre Morley (US) +1 609 216 5240 firstname.lastname@example.org Investors: Kasper Roseeuw Poulsen +45 4442 4303 email@example.com Frank Daniel Mersebach +45 4442 0604 firstname.lastname@example.org Lars Borup Jacobsen +45 3075 3479 email@example.com Jannick Lindegaard (US) +1 609 786 4575 firstname.lastname@example.org
Novo Nordisk A/S : FDA posts briefing materials prior to
Press spacebar to pause and continue. Press esc to stop.